» Articles » PMID: 28198554

Practical Approaches to Adverse Outcome Pathway Development and Weight-of-evidence Evaluation As Illustrated by Ecotoxicological Case Studies

Overview
Date 2017 Feb 16
PMID 28198554
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Adverse outcome pathways (AOPs) describe toxicant effects as a sequential chain of causally linked events beginning with a molecular perturbation and culminating in an adverse outcome at an individual or population level. Strategies for developing AOPs are still evolving and depend largely on the intended use or motivation for development and data availability. The present review describes 4 ecotoxicological AOP case studies, developed for different purposes. In each situation, creation of the AOP began in a manner determined by the initial motivation for its creation and expanded either to include additional components of the pathway or to address the domains of applicability in terms of chemical initiators, susceptible species, life stages, and so forth. Some general strategies can be gleaned from these case studies, which a developer may find to be useful for supporting an existing AOP or creating a new one. Several web-based tools that can aid in AOP assembly and evaluation of weight of evidence for scientific robustness of AOP components are highlighted. Environ Toxicol Chem 2017;36:1429-1449. © 2017 SETAC.

Citing Articles

Putative adverse outcome pathway development based on physiological responses of female fathead minnows to model estrogen versus androgen receptor agonists.

Morshead M, Jensen K, Ankley G, Vliet S, LaLone C, Aller A Aquat Toxicol. 2023; 261:106607.

PMID: 37354817 PMC: 10910347. DOI: 10.1016/j.aquatox.2023.106607.


Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.

Bajard L, Adamovsky O, Audouze K, Baken K, Barouki R, Beltman J Environ Res. 2022; 217:114650.

PMID: 36309218 PMC: 9850416. DOI: 10.1016/j.envres.2022.114650.


Adverse Outcome Pathways for Chronic Copper Toxicity to Fish and Amphibians.

Brix K, De Boeck G, Baken S, Fort D Environ Toxicol Chem. 2022; 41(12):2911-2927.

PMID: 36148934 PMC: 9828004. DOI: 10.1002/etc.5483.


Evaluation of effects-based methods as monitoring tools for assessing ecological impacts of metals in aquatic ecosystems.

Brix K, Blust R, Mertens J, Baken S, Middleton E, Cooper C Integr Environ Assess Manag. 2022; 19(1):24-31.

PMID: 35656908 PMC: 10084288. DOI: 10.1002/ieam.4645.


From Causal Networks to Adverse Outcome Pathways: A Developmental Neurotoxicity Case Study.

Ramsak Z, Modic V, Li R, Vom Berg C, Zupanic A Front Toxicol. 2022; 4:815754.

PMID: 35295214 PMC: 8915909. DOI: 10.3389/ftox.2022.815754.


References
1.
Naidoo V, Duncan N, Bekker L, Swan G . Validating the domestic fowl as a model to investigate the pathophysiology of diclofenac in Gyps vultures. Environ Toxicol Pharmacol. 2011; 24(3):260-6. DOI: 10.1016/j.etap.2007.06.003. View

2.
Carroll M, Catapane E . The nervous system control of lateral ciliary activity of the gill of the bivalve mollusc, Crassostrea virginica. Comp Biochem Physiol A Mol Integr Physiol. 2007; 148(2):445-50. PMC: 1986753. DOI: 10.1016/j.cbpa.2007.06.003. View

3.
Baraban S, Dinday M, Hortopan G . Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013; 4:2410. PMC: 3891590. DOI: 10.1038/ncomms3410. View

4.
Eldefrawi A, Eldefrawi M . Receptors for gamma-aminobutyric acid and voltage-dependent chloride channels as targets for drugs and toxicants. FASEB J. 1987; 1(4):262-71. DOI: 10.1096/fasebj.1.4.2443413. View

5.
Raftery T, Volz D . Abamectin induces rapid and reversible hypoactivity within early zebrafish embryos. Neurotoxicol Teratol. 2015; 49:10-8. DOI: 10.1016/j.ntt.2015.02.006. View